NEW YORK – Biotech Immunome has given the first patient with a solid tumor its fibroblast activation protein (FAP)-targeted radioligand therapy within a clinical trial, the company announced Monday.
If approved after priority review, the firm anticipates launching DYNE-251 in the US in the first quarter of next year.
Researchers are exploring delivering super-specific AAVs through the brain's natural waste disposal system, which can carry ...
A panel determined that Tafinlar and Adcetris will be offered to certain patients but passed on several other precision therapies.
The anti-amyloid drug is designed for a limited course, where patients can stop treatment once they reach a level of ...
The focus on treating people who have no cognitive impairment raises questions about how to implement testing for those at ...
After a promising Phase I read out on mKRAS-VAX in patients with hereditary cancer predisposition and pancreatic lesions, ...
NEW YORK – The US Food and Drug Administration has cleared Umoja Biopharma to begin a Phase I/II trial for its CD22-directed in vivo CAR T-cell therapy, UB-VV400, in patients with relapsed or ...
NEW YORK – Telix Pharmaceuticals has opened a new radiopharmaceutical manufacturing and treatment facility in Melbourne, Australia, the company announced Thursday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results